Upgrade to SI Premium - Free Trial

Form 3 Tango Therapeutics, Inc. For: Apr 15 Filed by: Newcomb Jessica

April 24, 2026 4:15 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Newcomb Jessica
(Last) (First) (Middle)
C/O TANGO THERAPEUTICS, INC.
201 BROOKLINE AVE., SUITE 901
(Street)
BOSTON MA 02215
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026 		3. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Principal Accounting Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 67,321 (1)
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (2) 09/01/2032 Common Stock 130,000 4.26 D
Stock Option (Right to Buy) (3) 03/01/2033 Common Stock 31,418 5.2 D
Stock Option (Right to Buy) (4) 06/01/2033 Common Stock 2,000 2.67 D
Stock Option (Right to Buy) (5) 02/01/2034 Common Stock 74,295 12.28 D
Stock Option (Right to Buy) (6) 01/02/2035 Common Stock 10,000 3.13 D
Stock Option (Right to Buy) (7) 02/03/2035 Common Stock 126,188 2.91 D
Stock Option (Right to Buy) (8) 01/02/2036 Common Stock 1,000 8.93 D
Stock Option (Right to Buy) (9) 02/02/2036 Common Stock 153,094 11.94 D
Explanation of Responses:
1. The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
2. This option vests and becomes exercisable over a four-year period, at a rate of 25% on August 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
3. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
4. This option is fully vested and exercisable.
5. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2025, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
6. This option vests and becomes exercisable over a four-year period, with the option shares vesting in 48 equal monthly installments beginning on January 14, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
7. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
8. This option vests and becomes exercisable over a one-year period, with the option shares vesting in 12 equal monthly installments beginning on November 23, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
9. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2027, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Remarks:
Exhibit 24: Power of Attorney
/s/ Julie Fogarty, as attorney-in-fact 04/24/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

EX-24

Categories

SEC Filings